Clinical Trial

Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-center, single-arm study evaluating the combination regimen of liposomal irinotecan, capecitabine, and enlonstobart combined with short-course radiotherapy as neoadjuvant therapy for locally advanced rectal cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-12; most recent amendment 2026-05-31.
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT07281157
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Advanced Rectal Cancer
Enrollment 30 participants
Start Date 2025-11-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2032-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03